Quarterly report pursuant to Section 13 or 15(d)

Schedule of Summarizes Information About Stock Options (Details)

v3.22.2.2
Schedule of Summarizes Information About Stock Options (Details)
$ / shares in Units, $ in Thousands
6 Months Ended
Jun. 30, 2022
USD ($)
$ / shares
shares
2014 Equity Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of Stock Options Outstanding, Beginning Balance | shares 8,720,198
Weighted Average Exercise Price, Beginning Balance | $ / shares $ 3.39
Remaining Contractual Term (Years) 6 years 9 months 18 days
Intrinsic Value Outstanding, Beginning Balance | $ $ 3,516 [1]
Number of Stock Options, Granted | shares 4,219,350 [2]
Weighted Average Exercise Price, Granted | $ / shares $ 1.49 [2]
Number of Stock Option, Exercised | shares (299,999)
Weighted Average Exercise Price, Exercised | $ / shares $ 1.01
Number of Stock Option, Forfeited | shares (1,437,143)
Weighted Average Exercise Price, Forfeited | $ / shares $ 3.04
Number of Stock Options Outstanding, Ending Balance | shares 11,202,406 [3]
Weighted Average Exercise Price, Ending Balance | $ / shares $ 2.79 [3]
Remaining Contractual Term (Years) 7 years 10 months 24 days [3]
Intrinsic Value Outstanding, Ending Balance | $ $ 8 [1],[3]
Number of Stock Options Vested and exercisable stock options | shares 5,994,046
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares $ 3.07
Remaining Contractual Term (Years), Vested and exercisable stock options 6 years 6 months
Intrinsic Value Exercisable, Ending Balance | $ $ 1 [1]
2018 Equity Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of Stock Options Outstanding, Beginning Balance | shares 1,419,242
Weighted Average Exercise Price, Beginning Balance | $ / shares $ 0.73
Remaining Contractual Term (Years) 7 years
Number of Stock Options, Granted | shares 2,107,500 [4]
Weighted Average Exercise Price, Granted | $ / shares $ 3.82 [4]
Number of Stock Option, Exercised | shares (959,389)
Weighted Average Exercise Price, Exercised | $ / shares $ 0.72
Number of Stock Option, Forfeited | shares (107,687)
Weighted Average Exercise Price, Forfeited | $ / shares $ 4.45
Number of Stock Options Outstanding, Ending Balance | shares 2,459,666 [5]
Weighted Average Exercise Price, Ending Balance | $ / shares $ 3.22 [5]
Remaining Contractual Term (Years) 9 years [5]
Number of Stock Options Vested and exercisable stock options | shares 741,869
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares $ 1.90
Remaining Contractual Term (Years), Vested and exercisable stock options 7 years 4 months 24 days
[1] The intrinsic value is computed as the difference between the quoted price of the PAVmed Inc. common stock on each of June 30, 2022 and December 31, 2021 and the exercise price of the underlying PAVmed Inc. stock options, to the extent such quoted price is greater than the exercise price.
[2] Stock options granted under the PAVmed Inc. 2014 Equity Plan and those granted outside such plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter-end, and have a ten-year contractual term from date-of-grant.
[3] The outstanding stock options presented in the table above, are inclusive of 500,854 stock options granted outside the PAVmed Inc. 2014 Equity Plan. as of June 30, 2022 and December 31, 2021.
[4] Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan and those granted outside such plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter, and have a ten-year contractual term from date-of-grant.
[5] The outstanding stock options presented in the table above, are inclusive of 423,300 stock options granted outside the Lucid Diagnostics Inc. 2018 Equity Plan. as of June 30, 2022 and December 31, 2021.